NeuBase Therapeutics, Inc.
DelistedCIK 1173281fmd_02AGCN6P0EJR9JKZW6PGP7MBBPManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Oct 01, 2006 to Sep 30, 2023, 57 periods
Latest annual · FY2022
Millions- Operating income
- (33)
- Net income
- (34)
- Free cash flow
- (29)
Latest quarter · Q3 FY2023
Millions- Operating income
- (3)
- Net income
- (2)
- Free cash flow
- (2)
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2017 to FY2022
- n/m
NeuBase Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2022 | FY2021 | Change | Source |
|---|---|---|---|---|
| Operating income | -$33.3 million | -$26.6 million | 10-K 2022-12-21 · proof | |
| Net income | -$33.8 million | -$25.4 million | 10-K 2022-12-21 · proof | |
| Cash from operating activities | -$29 million | -$18.9 million | 10-K 2022-12-21 · proof | |
| Free cash flow | -$29.5 million | -$20.3 million | 10-K 2022-12-21 · proof | |
| Total assets | $25.6 million | $57 million | -55.2% | 10-Q 2023-02-14 · proof |
| Total liabilities | $7.4 million | $9.9 million | -25.7% | 10-Q 2023-02-14 · proof |
| Cash and cash equivalents | $17.4 million | $47.3 million | -63.3% | 10-Q 2023-02-14 · proof |
- What was NeuBase Therapeutics, Inc.'s operating income in fiscal 2022?
- NeuBase Therapeutics, Inc. reported operating income of -$33.3 million for fiscal 2022 (the year ended Sep 30, 2022), against -$26.6 million the year before. Source: the 10-K filed with the SEC on Dec 21, 2022. SEC
- What was NeuBase Therapeutics, Inc.'s net income in fiscal 2022?
- NeuBase Therapeutics, Inc. reported net income of -$33.8 million for fiscal 2022 (the year ended Sep 30, 2022), against -$25.4 million the year before. Source: the 10-K filed with the SEC on Dec 21, 2022. SEC
- What was NeuBase Therapeutics, Inc.'s cash from operating activities in fiscal 2022?
- NeuBase Therapeutics, Inc. reported cash from operating activities of -$29 million for fiscal 2022 (the year ended Sep 30, 2022), against -$18.9 million the year before. Source: the 10-K filed with the SEC on Dec 21, 2022. SEC
- What was NeuBase Therapeutics, Inc.'s free cash flow in fiscal 2022?
- NeuBase Therapeutics, Inc. reported free cash flow of -$29.5 million for fiscal 2022 (the year ended Sep 30, 2022), against -$20.3 million the year before. Source: the 10-K filed with the SEC on Dec 21, 2022. SEC
- What are NeuBase Therapeutics, Inc.'s total assets?
- As of Dec 31, 2022, NeuBase Therapeutics, Inc. reported total assets of $25.6 million, against $57 million a year earlier (-55.2%). Source: the 10-Q filed with the SEC on Feb 14, 2023. SEC
- What are NeuBase Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2022, NeuBase Therapeutics, Inc. reported total liabilities of $7.4 million, against $9.9 million a year earlier (-25.7%). Source: the 10-Q filed with the SEC on Feb 14, 2023. SEC
- What are NeuBase Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2022, NeuBase Therapeutics, Inc. reported cash and cash equivalents of $17.4 million, against $47.3 million a year earlier (-63.3%). Source: the 10-Q filed with the SEC on Feb 14, 2023. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1173281&period_type=annual&limit=5"Information only, not investment advice.